

PERSONAL DATA

Name: Srinivasan Beddhu

Citizenship: United States

Office Address: Suite 360, 421 Wakara Way, Salt Lake City, UT 84108

EDUCATION

<u>Years</u>	<u>Degree</u>	<u>Institution (Area of Study)</u>
1981 - 1983		Don Bosco Higher Secondary School Tirupattur, NA, TN, India
1983 - 1989	M.B.B.S.	Stanley Medical College (Medicine) Madras, India
1989 - 1990	Resident	Stanley Medical College (Internal Medicine) Madras, India
1991 - 1992	Resident	Bangalore Medical College (Internal Medicine) Bangalore, India
1993 - 1996	Resident	St. Mary's Hospital of Rochester (Internal Medicine) Rochester, NY
1996 - 1999	Fellow	University Health Center of Pittsburgh (Nephrology) Pittsburgh, PA
1998 - 1999	Research Fellow	University of Pittsburg (Renal Division) Pittsburgh, PA

BOARD CERTIFICATIONS

09/01/1996 – 12/31/2027	American Board of Internal Medicine
11/01/1998 –	American Board of Internal Medicine, Nephrology

CURRENT LICENSES/CERTIFICATIONS

1992 - Present	Educational Commission for Foreign Medical Graduates
1999 - Present	State License (UT) - Physician (MD)
1999 - Present	Controlled Substance (UT) - Physician (MD)
2005 - Present	DEA Certificate (UT) - Physician (MD)

ACADEMIC HISTORY**Internal Medicine (Nephrology), 07/01/1999 - Present**

07/01/1999	Hire, Clinical/(Clinical) Track, Assistant Professor (Clinical)
01/01/2003	Track Switch, Tenure Track - Clinician Scholar, Assistant Professor
07/01/2006	Award of Tenure
07/01/2006	Promotion, Associate Professor
07/01/2012	Promotion, Professor

PROFESSIONAL EXPERIENCE

Full-Time Positions

2000 - 2003 Staff Physician, VAMC, Salt Lake City, UT

Part-Time Positions

1999 - 2000 Staff Physician, VAMC, Salt Lake City, UT

2003 - Present Staff Physician, VAMC, Salt Lake City, UT

Editorial Experience

2010 - 2018 Member, Editorial Board, Journal of Renal Nutrition

2012 - 2015 Editorial Board for Adipocyte Journal

2014 - Present Editorial Board for Clinical Journal of American Society of Nephrology

2016 - Present Editorial Board for Kidney International Report

Reviewer Experience

American Journal of Clinical Nutrition

American Journal of Kidney Disease

Annals of Internal Medicine

Clinical Journal of the American Society of Nephrology

Journal of Am Soc Nephrology

Journal of the Am College of Cardiology

Journal of the American Medical Association

Kidney International

Lancet

Nephrology Dialysis Transplantation

New England Journal of Medicine

SCHOLASTIC HONORS

1985 Sankunnie Marar Gold medal for proficiency in Physiology

1986 Microbiology Prize Examination Second Prize

1987 Merit Certificate of Honor in Pathology

1996 Best Outgoing Resident. Senior leadership award for excellence in knowledge, teaching and leadership qualities as a resident.

2005 William O'Dell Young Investigator Award, University of Utah

2006 Award of Tenure, University of Utah

2009 - 2012 Amundsen Endowed Chair in Medicine

2011 Golden Anniversary Alumni Prize for Distinguished Clinical Investigation, University of Utah

2014 - 2016 Amundsen Endowed Chair in Medicine

2018 - Dialysis Research Foundation Presidential Endowed Chair

ADMINISTRATIVE EXPERIENCE

Administrative Duties

1999 - 2007 Director, ESRD Program

VAMC, Salt Lake City, UT

Responsibilities included day to day administrative activities, quality control, interaction with nursing and technical staff, development and implementation of appropriate clinical protocols.

April 2019 – Chief, Renal Section
VAMC, Salt Lake City, UT
Responsibilities include leading the VA nephrology faculty, management of all clinical activities of the renal section, supervising nurse practitioner, working collaboratively with the nurses, pharmacist, dietician and social worker. I have worked closely with my colleagues to improve section productivity and access metrics. We have successfully used telehealth to expand our coverage in remote locations including in Idaho and Montana. We are working on starting a Home Dialysis program and expanding our existing in-center dialysis program.

March 2020- Clinical Research Medical Director,
Department of Internal Medicine (DOIM).
Responsibilities include facilitating clinical research in the Department. This includes improving access to resources such as DOIM Clinical Trials Unit, Data Science Services and Study Design & Bio-statistical Center for DOIM clinical researchers. I also started a Department wide Chalk Talk series to promote exchange of ideas and collaboration across the Divisions. We initiated surveys of users of these resources. The results of those surveys indicate productive utilization of the resources in terms of publications and federal funding.

Professional Organization & Scientific Activities

1999 - 2002 Member, National Institutes of Health, Outcomes committee HEMO trial
2001 - 2004 Member, National Kidney Foundation, K/DOQI Committee on Cardiovascular Disease in Hemodialysis
2007 Member, National Kidney Foundation, 2008 Clinical Meeting Program Committee
2008 Member, National Kidney Foundation, 2009 Clinical Meeting Program Committee
2009 - 2018 Member, National Institutes of Health, Systolic Pressure Intervention Trial (SPRINT) Measure, Procedure and Quality Control (MPQC) Committee
2009 - 2018 Member, National Institutes of Health, SPRINT Ancillary Science Committee (ASC)
2009 - 2018 Member, National Institutes of Health, SPRINT Utah Clinical Center Network (CCN) Steering Committee

Grant Review Committee/Study Section

2006 Reviewer, NIDDK (ZRG1 KNOD-N(01)Q) panel
2006 Reviewer, NIDDK SEP (ZRG1 RUS-A 51)
2006 Reviewer, NIDDK SEP (ZDK1 GRB-G J2)
2007 Reviewer, NIDDK SEP (ZRG1 RUS-A (51) (1)
2007 Reviewer, NIDDK SEP (ZDK1 GRB-G J2)
2008 Member, National Kidney Foundation Research Committee
2008 Reviewer, NIDDK SEP (ZDK1 GRB-O1) O'Brien Center
2008 Reviewer, NIDDK SEP ZDK1 GRB-7 (M1)
2008 Reviewer, NIDDK (ZRG1 KNOD-N(01)Q)
2008 Reviewer, NIDDK ZRG1 EMNR-E (10) B
2008 Reviewer, NIDDK SEP ZRG1 RUS-F (51) S
2009 Member, National Kidney Foundation Research Committee
2009 Reviewer, NIDDK ZDK1 GRB-S (O1) 2
2010 Chair, NIDDK ZDK1 GRB-7 (J4) 1
2010 Member, NIDDK ZDK1 GRB-G (M1) 1
2011 Member, National Kidney Foundation Research Committee

2011	Reviewer, NIDDK ZDK1 GRB7 (M4) 1
2011	Reviewer, NIDDK ZDK1 GRB (S) 05
2012	Reviewer, ZDK1 GRB-6 (M3)
2012	Ad-hoc reviewer, NIH PBKD Study section
2012	Reviewer, ZDK1 GRB-7 (O3) S
2013	Reviewer, 2013/05 ZKD1 GRB-C (M1) 1
2013 - 2018	American Society of Nephrology Study Review Committee
2020 -	Member, NIDDK DDK-D Study Section

Symposium/Meeting Chair/Coordinator

2003	Abstract Reviewer, ASN
2006	Abstract Reviewer, ASN
2007	Member, Clinical Meeting Program Committee, NKF
2008	Member, Clinical Meeting Program Committee, NKF
2010	Abstract Reviewer, ASN
2011	Abstract Reviewer, ASN
2012	Abstract Reviewer, ASN
2013	Abstract Category Chair (CKD: Epidemiology and Outcomes)
2014	Abstract Reviewer, ASN
2015	Abstract Reviewer, ASN
2018 - 2019	Member, 2019 ASN Program Committee

UNIVERSITY COMMUNITY ACTIVITIES

Health Sciences Level

2009 - 2015	Steering Committee Member, Study Design and Biostatistics Center Core
-------------	---

College Level

2000 - 2003	Member, School of Medicine Institutional Review Board
-------------	---

Department Level

2019-2021	Member, Tenured Faculty Retention Committee
-----------	---

Division Level

2007 - 2014	Member, Nephrology, Fellowship Steering Committee
2010 - 2012	Member, Nephrology, T32 Steering Committee

CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIES

American Society of Nephrology
 International Society of Nephrology
 National Kidney Foundation

FUNDING

Active Grants

- 09/01/2018 – 07/31/2023
(Under NCE) Long-term metabolic effects of kidney events with intensive SBP control
Principal Investigators: Srinivasan Beddhu and Glenn Chertow
NIH National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK)
1R01DK118219
Role: Contact Principal Investigator
Total Award Amount (including Indirect Costs): **\$1,157,452**
- 05/15/2021 – 04/30/2026 Sit Less, Interact and Move More (SLIMM) 2
Principal Investigator: Srinivasan Beddhu
NIH National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK)
1R01DK128640
Role: Principal Investigator
Total Award Amount (including Indirect Costs): **\$3,299,008**
- 07/15/2021 – 03/31/2026 Objectively Measured Sedentary Behavior and Physical Activity in
PREVENTABLE Study
Principal Investigator: Srinivasan Beddhu
NIH National Institute of Aging (NIA)
1R01AG074592-01
Role: Principal Investigator
Total Award Amount (including Indirect Costs): **\$3,390,913**
- 08/01/2021 – 07/31/2025 Remote Monitoring and Virtual Collaborate Care for Hypertension Control
to Prevent Cognitive Decline
Principal Investigators: Jeffrey Burns, Aditi Gupta, Russell Waitman
4R33AG068483-02
Role: Site Principal Investigator
Utah Total Award Amount (including Indirect Costs): **\$3,525,623**
- 03/01/2022-02/28/2023 MSRP in Metabolism, Diabetes, Digestive and Kidney Diseases
Principal Investigators: Srinivasan Beddhu, June Round
NIH National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK)
T35 DK103596
Role: Principal Investigator
Total Award Amount (including Indirect Costs): **\$321,910**
- 10/2021 – 09/2023 Racial and Ethnic Disparities in Renal Replacement Therapy in Rural
Veterans
Principal Investigator: Srinivasan Beddhu
VA ORH-14398
Role: Principal Investigator
- 08/2021- 07/2028 Pentoxifylline in Diabetic Kidney Disease (PTXRx)
Principal Investigator: David J. Leehey

VA CSP-2008

Role: Site Principal Investigator

Past NIH/ AHRQ Grants

- 08/01/1999 - 05/30/2002 The HEMO Study Utah Clinical Site
National Institutes of Health
Role: Co-Principal Investigator of the site
- 05/01/2001 - 04/30/2003 Comorbidity, Costs and Outcomes in Dialysis Patients. The major goal of this project was to develop an ESRD specific comorbidity index
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$66,500 Total Costs: \$99,750
Agency for Healthcare Research and Quality
Role: Principal Investigator
- 09/10/2007 - 08/31/2012 Protein Intake, Nutrition, and cardiovascular disease in CKD Stage V
RO1-DK077298
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$1,073,002 Total Costs: \$1,432,032
National Institute of Diabetes and Digestive and Kidney Diseases
Role: Principal Investigator
- 08/01/2008 - 04/30/2012 Adipokines In Hemodialysis Patients
RO1- DK078112
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$1,606,150 Total Costs: \$2,174,844
National Institute of Diabetes and Digestive and Kidney Diseases
Role: Principal Investigator
- 06/01/2011 - 05/31/2018 SPRINT – Factors Affecting Atherosclerosis Study (FAST)
R01 DK091437
National Institute of Diabetes and Digestive and Kidney Diseases
Role: Principal Investigator
Direct Costs: \$1,729,984 Total Costs: \$2,287,297
- 09/01/2011 - 08/31/2015 Role: Principal Investigator
Pulse Wave Velocity and Central Aortic Pressure Outcomes in SPRINT
Principal Investigator: Mark Supiano
National Institutes of Health
Role: Co-Investigator
- 09/14/2009 - 08/30/2018 Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks
Principal Investigator: Alfred K. Cheung
Direct Costs: \$1,386,886 Total Costs: \$1,840,397
HHSN268200900046C, National Heart, Lung, and Blood Institute
Role: Co-Investigator
- 11/15/2016 – 06/30/2019 Sit Less, Interact, Move More (SLIMM) Intervention for Sedentary Behavior in CKD
Principal Investigator: Srinivasan Beddhu

Direct Costs: \$152,533 Total Costs: \$226,500

R21DK106574

National Institutes of Health

Role: Principal Investigator

- 02/01/2019 – 01/31/2022 Influence of baseline DBP on the effects of BP lowering on clinical outcomes: A participant level meta-analysis of RCTs
Principal Investigator: Srinivasan Beddhu
1R21HL145494-01
NIH Advancing Heart, Lung, Blood and Sleep Research (NHLBI)
Role: Principal Investigator
- 08/17/2017 – 06/30/2022 Blood Pressure and Kidney Function – SPRINT vs Electronic Health Record Data
Principal Investigator: Paul Drawz
NIH Advancing Heart, Lung, Blood and Sleep Research (NHLBI)
1R01HL136679
Role: Co-Investigator
Total Award Amount (including Indirect Costs)
- 08/01/2019 – 09/30/2021 HiLo: Pragmatic trial of higher vs lower serum phosphate targets in patients undergoing hemodialysis
Principal Investigator: Myles wolf
NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
5UGH3DK118748-03
Role: Co-Investigator
Utah Total Award Amount (including Indirect Costs)
- Past Non –NIH grants**
- 06/01/2000 - 06/30/2001 The Impact of Early Initiation of Hemodialysis on Serum Albumin, Hospitalization, Costs and Mortality.
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$36,867 Total Costs: \$36,867
Dialysis Research Foundation of Utah
Role: Principal Investigator
- 07/01/2000 - 06/30/2002 Uremia and Inflammation: Does C-reactive Protein Concentrations Increase with Progressive Chronic Renal Failure?
Principal Investigator: Srinivasan Beddhu
Western Institute For Biomedical Research, Inc.
Role: Principal Investigator
- 03/01/2002 - 02/28/2004 Peripheral vascular disease in dialysis patients.
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$37,333 Total Costs: \$37,333
Dialysis Research Foundation of Utah
Role: Principal Investigator

- 06/01/2002 - 05/30/2003 Impact of Malnutrition and Obesity on Cardiovascular Outcomes in Dialysis Patients.
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$7,500 Total Costs: \$7,500
National Kidney Foundation of Utah
Role: Principal Investigator
- 01/01/2003 - 12/31/2004 Atherosclerosis in dialysis patients: Risk factors and medication prescription patterns.
The major goal of this project is to examine risk factors for atherosclerosis in URSDS data
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$40,000 Total Costs: \$40,000
Dialysis Research Foundation of Utah
Role: Principal Investigator
- 09/01/2003 - 08/31/2004 Protein intake, nutritional status and survival in dialysis patients
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$18,500 Total Costs: \$18,500
National Kidney Foundation of Utah
Role: Principal Investigator
- 05/01/2004 - 04/30/2006 Nutrition and Timing of Dialysis.
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$54,665 Total Costs: \$54,665
Dialysis Research Foundation of Utah
Role: Principal Investigator
- 09/01/2004 - 08/31/2005 Nutrition and glomerular filtration rate assessment: The Third National Health and Nutrition Examination Survey
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$15,000 Total Costs: \$15,000
National Kidney Foundation of Utah
Role: Principal Investigator
- 07/01/2007 - 08/31/2008 Adiponectin And Anemia in Chronic Kidney Disease
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$53,700 Total Costs: \$53,700
Dialysis Research Foundation of Utah
Role: Principal Investigator
- 09/01/2008 - 08/31/2010 Muscle Wasting in Uremia
Principal Investigator: Srinivasan Beddhu
Direct Costs: \$87,808 Total Costs: \$87,808
Dialysis Research Foundation
Role: Principal Investigator
- 07/01/2009 - 06/30/2011 Effects of cholecalciferol replacement on inflammation and insulin resistance in hemodialysis patients on therapeutic doses of paricalcitol.
Principal Investigator: Vidya Raj Krishnamurthy

Direct Costs: \$100,000 Total Costs: \$100,000
 National Kidney Foundation Research Fellowship Award
 Role: Primary Mentor
 07/01/2010 - 06/30/2011 Effects of oral calcium carbonate therapy on serum fibroblast growth factor 23 and markers of inflammation and oxidative stress markers in CKD patients with high phosphaturia: a cross-over study.
 Principal Investigator: Magdalena Sikora
 Direct Costs: \$15,000 Total Costs: \$15,000
 National Kidney Foundation of Utah
 Role: Primary Mentor

03/01/2011 - 03/14/2013 Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic CKD.
 Principal Investigator: Srinivasan Beddhu
 Direct Costs: \$530,800 Total Costs: \$704,372
 Takeda Pharmaceuticals North America, Inc.
 Role: Principal Investigator

05/01/2012 - 04/30/2013 Mind The Kidneys
 Direct Costs: \$74,623 Total Costs: \$111,450
 Biomedical Support Research Grant
 Role: Utah Site Principal Investigator

09/03/2012 - 08/31/2016 Harold Amos Medical Faculty Development Award
 Principal Investigator: Kalani L. Raphael
 Robert Wood Johnson Foundation
 Role: Mentor

10/18/2013 – 05/01/2018 A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with type 2 Diabetes and Nephropathy- SONAR: Study of Diabetic Nephropathy with Atrasentan
 Principal Investigator: Srinivasan Beddhu
 Direct Costs: \$112,012 Total Costs: \$148,640
 AbbVie Inc.
 Role: Principal Investigator

10/01/2015 - 09/30/2016 Nutri-Neph Supplement Study
 Principal Investigator: Srinivasan Beddhu
 Direct Costs: \$30,143 Total Costs: \$40,000
 Nourish & Strengthen
 Role: Principal Investigator

11/15/2015 – 01/31/2020 A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the safety and efficacy of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. 16244
 Direct Costs: \$298,769 Total Costs: \$385,868
 Bayer
 Role: Site Principal Investigator

- 11/15/2015 – 01/31/2020 A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the safety and efficacy of finerenone, in addition to standard of care, on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. 17530
Direct Costs: \$298,769 Total Costs: \$385,868
Bayer
Role: Site Principal Investigator
- 02/01/2019 – 01/31/2022 Salt Lake City VA Dialysis Quality Initiative
Principal Investigator: Srinivasan Beddhu
VA Office of Rural Health
VA ORH-14398
Role: Principal Investigator

TEACHING RESPONSIBILITIES/ASSIGNMENTS

Courses Directed

2002 - 2012 Nephrology Fellows Weekly Clinical Conference

Course Lectures

- 2002 Instructor, INTMD 7070: Nephrology OS - Urinalysis, University of Utah, Internal Medicine
- 2003 Instructor, INTMD 7070: Nephrology OS - Hypertension, University of Utah, Internal Medicine
- 2003 Instructor, PATH 6020 (1): Pathology - Pharmacology and Therapeutics of ESRD, University of Utah, Pathology
- 2004 Instructor, PHYSL 6070 (1): Physiology 6070 - 4 - Disorders of Potassium Homeostasis, University of Utah, Physiology
- 2004 Instructor, PH TX 6020 (1): Pharmacology 6020- 2 - Pharmacology and Therapeutics of ESRD, University of Utah, Pharmacology and Toxicology
- 2006 Instructor, INTMD 7070 (1): Nephrology OS - 5 - Disorders of Potassium Homeostasis, University of Utah, Internal Medicine
- 2007 Instructor, INTMD 7070 (1): Nephrology - Potassium Disorders, University of Utah, Internal Medicine
- 2008 Instructor, INTMD 7070 (1): Nephrology OS- 5 - Pathophysiology of Potassium, University of Utah, Internal Medicine
- 2009 Instructor, INTMD 7070 (1): Nephrology OS- 5 - Pathophysiology of Potassium, University of Utah, Internal Medicine
- 2010 Instructor, INTMD 7070 (1): Nephrology OS- 5 - Pathophysiology of Potassium, University of Utah, Internal Medicine
- 2011 Instructor, MD ID (1): Medical Science - Glomerular Disease, University of Utah, Office of the Dean/Medicine
- 2011 Instructor, MD ID (1): Medical Science - Renal Failure, University of Utah, Office of the Dean/Medicine
- 2011 Instructor (1): MS2014 CRR - Renal Failure Cases - Facilitators, University of Utah
- 2015 Facilitator, INTMD: Circulation, Respiration, and Regulation - Renal Physiology Cases, University of Utah, Internal Medicine
- 2015 Facilitator, INTMD: Circulation, Respiration, and Regulation - Renal Failure Cases,

University of Utah, Internal Medicine

Clinical Teaching

1999 - Present Teaching of Nephrology Fellows, Residents, and medical students

Small Group Teaching

2005 Instructor, INTMD 7070(1): Nephrology OS - Small Groups II - Salt and Water, University of Utah, Internal Medicine
2005 Instructor, INTMD 7070(1): Nephrology OS - Small Groups III - Acid Base, University of Utah, Internal Medicine
2006 Instructor, INTMD 7070(1): Nephrology OS - 5 - Small Groups: Disorders of Volume, Tonicity and Potassium Homeostasis, University of Utah, Internal Medicine
2007 Instructor, INTMD 7070(1): Nephrology - Small groups - Renal Failure, University of Utah, Internal Medicine
2009 Instructor, INTMD 7070(1): Nephrology OS- 5 - Small Groups: Renal Failure, University of Utah, Internal Medicine

Trainee Supervision

Faculty

2010 - 2014 Mentor, John Nord, MD, University of Utah
2010 - 2015 Mentor, Kalani Raphael, MD, University of Utah, VA Career Development Award

Fellow/ Post-doc

2002 - 2004 Mentor, Don Morris, MD, University of Utah, Nephrology Fellow
2005 - 2006 Mentor, Bonnie Kwan, University of Utah, Research Fellow
2009 - 2011 Mentor, Vidya Raj Krishnamurthy, MD, University of Utah, Research Fellow
Obtained NKF Fellowship Grant
2010 - 2012 Mentor, Swetha Boddada, University of Utah, Post-Doctoral Fellow
2010 - 2013 Mentor, Magdalena Sikora, MD, University of Utah, Research Fellow.
2010 - 2013 Mentor, Shanying Chen, University of Utah, Post-Doctoral Fellow
2011 - 2013 Mentor, Nestor E. Almedia, MD, University of Utah, Research Fellow
Obtained NKF Fellowship Grant.
2013 - 2014 Mentor, Bin Wang, MD, University of Utah, Research Fellow
2017 - 2019 Mentor, Catreena Al Marji, University of Utah
2019 - 2020 Mentor, Na Zhou, MD, University of Utah, Research Fellow
2020 - 2022 Mentor, Olesya Ilkun, MD, PhD University of Utah, Research Fellow
2021 – Mentor, Amara Sarwal, MD, University of Utah, Research Fellow

Resident

2004 - 2005 Mentor, Chris Logar, MD, University of Utah, Medical Resident
2008 - 2009 Mentor, Sriharsha Damera, MD, University of Utah, Medical Resident
2010 - 2012 Mentor, Neelakanta Dadi, MD, University of Utah, Medical Resident
2011 - 2012 Mentor, Tahir Zaman, MD, University of Utah, Medical Resident.
2011 - 2013 Mentor, Macy Martensen, MD, University of Utah, Medical Resident
2018 - 2020 Mentor, Olesya Ilkun, MD, PhD, University of Utah, Medical Resident
2019 - Mentor, Sydney Hartsell, MD, MPH, University of Utah, Medical Resident
2021 - Mentor, Steven Sammons, MD, University of Utah, Medical Resident

PhD

2021- Mentor, Ravi Singh, MS, University of Utah PHS PhD Program

2022 - Mentor, Farahnaz Akramimoghaddam, BS, Univ. of Utah NUIP PhD Program

Masters

2002 - 2006 Mentor, Nirupama Ramkumar, University of Utah, MSPH
2008 - 2009 Mentor, Matthew Johnson, University of Utah, MS
2010 - 2012 Mentor, Radhika Deshmukh, University of Utah, MPH
2013 - 2014 Mentor, Xiaouri Chen, University of Utah, MPH
2013 - 2014 Mentor, Natalie Anderton, University of Utah, DPT
2014 - 2016 Mentor, Xiaorui Chen, University of Utah, MS
2015 - 2017 Mentor, Ajay Giri, University of Utah, MS
2021 - Mentor, Nikita Abraham, University of Utah, MPH

Graduate Student Committees

2014 - 2015 Chair, John Nord, University of Utah, Masters Committee. Students Thesis Committee
2014 - 2015 Member, Xiaorui Chen, University of Utah, Masters Committee. Student Thesis Committee

PUBLICATIONS

(Google Scholar H-index 55, i10-index 107, citations 10168)

PEER-REVIEWED JOURNAL ARTICLES

1. **Beddhu S**, Bruns FJ, Saul M, Seddon P, Zeidel ML (2000). A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. *Am J Med*, 108(8), 609-13.
2. **Beddhu S**, Zeidel ML, Saul M, Seddon P, Samore MH, Stoddard GJ, Bruns FJ (2002). The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. *Am J Med*, 112(9), 696-701.
3. **Beddhu S**, Bastacky S, Johnson JP (2002). The clinical and morphologic spectrum of renal cryoglobulinemia. *Medicine (Baltimore)*, 81(5), 398-409.
4. **Beddhu S**, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK (2002). Association of serum albumin and atherosclerosis in chronic hemodialysis patients. *Am J Kidney Dis*, 40(4), 721-7.
5. **Beddhu S**, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL (2002). Impact of renal failure on the risk of myocardial infarction and death. *Kidney Int*, 62(5), 1776-83.
6. **Beddhu S** (2003). Say "no" and comorbidity. *Am J Kidney Dis*, 42(2), 429-30.
7. **Beddhu S**, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK (2003). Creatinine production, nutrition, and glomerular filtration rate estimation. *J Am Soc Nephrol*, 14(4), 1000-5.
8. Allon M, Depner TA, Radeva M, Bailey J, **Beddhu S**, Butterly D, Coyne DW, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ (2003). Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. *J Am Soc Nephrol*, 14(7), 1863-70.
9. Zebrack JS, Anderson JL, **Beddhu S**, Horne BD, Bair TL, Cheung A, Muhlestein JB (2003). Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? *J Am Coll Cardiol*, 42(1), 57-63.
10. **Beddhu S**, Pappas LM, Ramkumar N, Samore M (2003). Effects of body size and body composition on survival in hemodialysis patients. *J Am Soc Nephrol*, 14(9), 2366-72.
11. **Beddhu S**, Samore MH, Roberts MS, Stoddard GJ, Ramkumar N, Pappas LM, Cheung AK (2003). Impact of timing of initiation of dialysis on mortality. *J Am Soc Nephrol*, 14(9), 2305-12.
12. **Beddhu S**, Pappas LM, Ramkumar N, Samore MH (2004). Malnutrition and atherosclerosis in dialysis patients. *J Am Soc Nephrol*, 15(3), 733-42.
13. Unruh M, Benz R, Greene T, Yan G, **Beddhu S**, DeVita M, Dwyer JT, Kimmel PL, Kusek JW,

- Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB (2004). Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. *Kidney Int*, 66(1), 355-66.
14. Ramkumar N, Cheung AK, Pappas LM, Roberts WL, **Beddhu S** (2004). Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. *J Ren Nutr*, 14(4), 201-7.
 15. **Beddhu S**, Ramkumar N, Samore MH (2005). The paradox of the "body mass index paradox" in dialysis patients: associations of adiposity with inflammation. *Am J Clin Nutr*, 82(4), 909-11.
 16. **Beddhu S**, Pappas LM, Ramkumar N, Samore MH (2005). Body mass index and survival in incident dialysis patients: the answer depends on the question. *Am J Clin Nutr*, 81(2), 534-6.
 17. Logar CM, Pappas LM, Ramkumar N, **Beddhu S** (2005). Surgical revascularization versus amputation for peripheral vascular disease in dialysis patients: a cohort study. *BMC Nephrol*, 6(1), 3.
 18. Morris D, Samore MH, Pappas LM, Ramkumar N, **Beddhu S** (2005). Nutrition and racial differences in cardiovascular events and survival in elderly dialysis patients. *Am J Med*, 118(6), 671-5.
 19. Allon M, Radeva M, Bailey J, **Beddhu S**, Butterly D, Coyne DW, Depner TA, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ, HEMO Study Group (2005). The spectrum of infection-related morbidity in hospitalized hemodialysis patients. *Nephrol Dial Transplant*, 20(6), 1180-6.
 20. Ramkumar N, **Beddhu S**, Eggers P, Pappas LM, Cheung AK (2005). Patient preferences for in-center intense hemodialysis. *Hemodial Int*, 9(3), 281-95.
 21. Ramkumar N, Pappas LM, **Beddhu S** (2005). Effect of body size and body composition on survival in peritoneal dialysis patients. *Perit Dial Int*, 25(5), 461-9.
 22. **Beddhu S**, Kimmel PL, Ramkumar N, Cheung AK (2005). Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III). *Am J Kidney Dis*, 46(4), 577-86.
 23. **Beddhu S**, Ramkumar N, Pappas LM (2005). Normalization of protein intake by body weight and the associations of protein intake with nutritional status and survival. *J Ren Nutr*, 15(4), 387-97.
 24. Delmez JA, Yan G, Bailey J, Beck GJ, **Beddhu S**, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ (2006). Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. *Am J Kidney Dis*, 47(1), 131-8.
 25. **Beddhu S** (2006). If fat is good, muscle is better. *Am J Kidney Dis*, 47(1), 193-4.
 26. Kwan BC, **Beddhu S**, Kronenberg F, Cheung AK (2006). Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? *Nat Clin Pract Nephrol*, 2(2), 76-7.
 27. Ng YH, Meyer KB, Kusek JW, Yan G, Rocco MV, Kimmel PL, Benz RL, **Beddhu S**, Dwyer JT, Toto RD, Eknoyan G, Unruh ML (2006). Hemodialysis timing, survival, and cardiovascular outcomes in the Hemodialysis (HEMO) Study. *Am J Kidney Dis*, 47(4), 614-24.
 28. Ramkumar N, Murtaugh MA, Cheung AK, **Beddhu S** (2007). Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. *Am J Kidney Dis*, 49(3), 356-64.
 29. Kwan BC, Murtaugh MA, **Beddhu S** (2007). Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. *Clin J Am Soc Nephrol*, 2(5), 992-8.
 30. **Beddhu S**, Cheung AK, Larive B, Greene T, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G (2007). Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. *J Ren Nutr*, 17(6), 372-80.
 31. Unruh ML, Newman AB, Larive B, Dew MA, Miskulin DC, Greene T, **Beddhu S**, Rocco MV, Kusek JW, Meyer KB (2008). The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis. *J Am Geriatr Soc*, 56(9), 1608-17.
 32. Navaneethan SD, **Beddhu S** (2009). Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. *Nephrol Dial Transplant*, 24(4), 1260-6.

33. **Beddhu S**, Nigwekar SU, Ma X, Greene T (2009). Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. *Nephrol Dial Transplant*, 24(8), 2482-8.
34. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, **Beddhu S** (2009). Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol*, 4(10), 1565-74.
35. **Beddhu S**, Ma X, Baird B, Cheung AK, Greene T (2009). Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol*, 4(11), 1805-10.
36. **Beddhu S**, Baird BC, Zitterkoph J, Neilson J, Greene T (2009). Physical activity and mortality in chronic kidney disease (NHANES III). *Clin J Am Soc Nephrol*, 4(12), 1901-6.
37. Huang CX, Tighiouart H, **Beddhu S**, Cheung AK, Dwyer JT, Eknoyan G, Beck GJ, Levey AS, Sarnak MJ (2010). Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. *Kidney Int*, 77(7), 624-9.
38. **Beddhu S**, Baird B, Ma X, Cheung AK, Greene T (2010). Serum alkaline phosphatase and mortality in hemodialysis patients. *Clin Nephrol*, 74(2), 91-6.
39. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, **Beddhu S** (2011). Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. *Kidney Int*, 79(2), 228-33.
40. Raphael KL, Wei G, Baird BC, Greene T, **Beddhu S** (2011). Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. *Kidney Int*, 79(3), 356-62.
41. Krishnamurthy VR, Baird BC, Wei G, Greene T, Raphael K, **Beddhu S** (2011). Associations of serum alkaline phosphatase with metabolic syndrome and mortality. *Am J Med*, 124(6), 566.e1-7.
42. Scialla JJ, Appel LJ, Astor BC, Miller ER 3rd, **Beddhu S**, Woodward M, Parekh RS, Anderson CA (2011). Estimated net endogenous acid production and serum bicarbonate in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol*, 6(7), 1526-32.
43. Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, **Beddhu S**, Roberts WL (2011). Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. *Ann Clin Lab Sci*, 41(4), 331-9.
44. Raphael KL, Wei G, Greene T, Baird BC, **Beddhu S** (2012). Cognitive function and the risk of death in chronic kidney disease. *Am J Nephrol*, 35(1), 49-57.
45. Sikora MB, Shaaban A, **Beddhu S**, Bourija H, Wei G, Baird B, Truax CM, Shihab FS (2012). Effect of donor kidney volume on recipient outcome: does the "dose" matter? *Transplantation*, 94(11), 1124-30.
46. Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T, **Beddhu S** (2012). High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. *Kidney Int*, 81(3), 300-6.
47. Murtaugh MA, Filipowicz R, Baird BC, Wei G, Greene T, **Beddhu S** (2012). Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. *Nephrol Dial Transplant*, 27(3), 990-6.
48. Scialla JJ, Appel LJ, Astor BC, Miller ER 3rd, **Beddhu S**, Woodward M, Parekh RS, Anderson CA (2012). Net endogenous acid production is associated with a faster decline in GFR in African Americans. *Kidney Int*, 82(1), 106-12.
49. Sikora MB, Shaaban A, **Beddhu S**, Bourija H, Wei G, Baird B, Truax CM, Shihab FS (2012). Effect of donor kidney volume on recipient outcome: does the "dose" matter? *Transplantation*, 94(11), 1124-30.
50. Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, Baird BC, **Beddhu S** (2013). Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. *Clin J Am Soc Nephrol*, 8(1), 26-32.

51. Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, Baird BC, **Beddhu S** (2013). Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. *Clin J Am Soc Nephrol*, 8(1), 26-32.
52. Raphael KL, Zhang Y, Wei G, Greene T, Cheung AK, **Beddhu S** (2013). Serum bicarbonate and mortality in adults in NHANES III. *Nephrol Dial Transplant*, 28(5), 1207-13.
53. Raphael KL, Zhang Y, Wei G, Greene T, Cheung AK, **Beddhu S** (2013). Serum bicarbonate and mortality in adults in NHANES III. *Nephrol Dial Transplant*, 28(5), 1207-13.
54. Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, **Beddhu S**, Nally JV Jr (2013). Metabolic Syndrome, ESRD, and Death in CKD. *Clin J Am Soc Nephrol*, 8(6), 945-52.
55. Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, **Beddhu S**, Nally JV Jr (2013). Metabolic syndrome, ESRD, and death in CKD. *Clin J Am Soc Nephrol*, 8(6), 945-52.
56. Su CT, Yabes J, Pike F, Weiner DE, **Beddhu S**, Burrowes JD, Rocco MV, Unruh ML (2013). Changes in anthropometry and mortality in maintenance hemodialysis patients in the HEMO Study. *Am J Kidney Dis*, 62(6), 1141-50.
57. Su CT, Yabes J, Pike F, Weiner DE, **Beddhu S**, Burrowes JD, Rocco MV, Unruh ML (2013). Changes in anthropometry and mortality in maintenance hemodialysis patients in the HEMO Study. *Am J Kidney Dis*, 62(6), 1141-50.
58. Guo X, Zhou G, Guo M, Cheung AK, Huang Y, **Beddhu S** (2014). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. *Physiol Rep*, 2(2), e00230.
59. Guo X, Zhou G, Guo M, Cheung AK, Huang Y, **Beddhu S** (2014). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. *Physiological Reports*, 2(2).
60. Kaskel F, Batlle D, **Beddhu S**, Daugirdas J, Feldman H, Ferris M, Fine L, Freedman BI, Kimmel PL, Flessner MF, Star RA, Kidney Research National Dialogue (KRND) (2014). Improving CKD Therapies and Care: A National Dialogue. *Clin J Am Soc Nephrol*, 9(4), 815-7.
61. Kaskel F, Batlle D, **Beddhu S**, Daugirdas J, Feldman H, Ferris M, Fine L, Freedman BI, Kimmel PL, Flessner MF, Star RA (2014). Improving CKD therapies and care: a National Dialogue. *Clin J Am Soc Nephrol*, 9(4), 815-7.
62. Martinson M, Ikizler TA, Morrell G, Wei G, Almeida N, Marcus RL, Filipowicz R, Greene TH, **Beddhu S** (2014). Associations of Body Size and Body Composition with Functional Ability and Quality of Life in Hemodialysis Patients. *Clin J Am Soc Nephrol*.
63. Martinson M, Ikizler TA, Morrell G, Wei G, Almeida N, Marcus RL, Filipowicz R, Greene TH, **Beddhu S** (2014). Associations of body size and body composition with functional ability and quality of life in hemodialysis patients. *Clin J Am Soc Nephrol*, 9(6), 1082-90.
64. **Beddhu S**, Filipowicz R, Chen X, Neilson JL, Wei G, Huang Y, Greene T (2015). Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study. *BMC Nephrol*, 16(87).
65. Anderton N, Giri A, Wei G, Marcus RL, Chen X, Bjordahl T, Habib A, Herrera J, **Beddhu S** (2015). Sedentary Behavior in Individuals with Diabetic Chronic Kidney Disease and Maintenance Hemodialysis. *J Ren Nutr*, 25(4), 364-70.
66. **Beddhu S**, Wei G, Marcus RL, Chonchol M, Greene T (2015). Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. *Clin J Am Soc Nephrol*, 10(7), 1145-53.
67. Raphael KL, **Beddhu S** (2015). Hypertension and Polypharmacy in Elderly Nursing Home Residents: When Less is More. *Am J Kidney Dis*, 66(4), 561-3.
68. Chertow GM, **Beddhu S**, Lewis JB, Toto RD, Cheung AK (2016). Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT. *J Am Soc Nephrol*, 27(1), 40-3.
69. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine

- LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*, 373(22), 2103-16.
70. Chen X, Wei G, Jalili T, Metos J, Giri A, Cho ME, Boucher R, Greene T, **Beddhu S** (2016). The Associations of Plant Protein Intake with All-Cause Mortality in CKD. *Am J Kidney Dis*, 67(3), 423-30.
 71. Chen X, **Beddhu S** (2015). Food for Thought: Diet as a Risk Factor for CKD. *Am J Nephrol*, 42(6), 425-6.
 72. Marcus RL, LaStayo PC, Ikizler TA, Wei G, Giri A, Chen X, Morrell G, Painter P, **Beddhu S** (2015). Low Physical Function in Maintenance Hemodialysis Patients Is Independent of Muscle Mass and Comorbidity. *J Ren Nutr*, 25(4), 371-5.
 73. Chen X, Ikizler TA, Heilbrun ME, Wei G, Boucher R, **Beddhu S**, Morrell GR (2016). Psoas Muscle Cross-section Area as a Measure of Whole-body Lean Muscle Mass in Maintenance Hemodialysis Patients. *J Ren Nutr*, 26(4), 258-64.
 74. Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, **Beddhu S**, Rosendorff C, Jahanian H, Zaharchuk G, SPRINT Study Research Group (2016). Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. *Neurology*, 86(13), 1208-16.
 75. **Beddhu S**, Filipowicz R, Wang B, Wei G, Chen X, Roy AC, DuVall SL, Farrukh H, Habib AN, Bjordahl T, Simmons DL, Munger M, Sottdard G, Kohan DE, Greene T, Huang Y (12/05/2016). A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. *Can J Kidney Health Dis*, 3.
 76. Odden MC, Peralta CA, Berlowitz DR, Johnson KC, Whittle J, Kitzman DW, **Beddhu S**, Nord JW, Papademetriou V, Williamson JD, Pajewski NM, Systolic Blood Pressure Intervention Trial (SPRINT) Research Group (04/01/2017). Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older: A Randomized Clinical Trial. *JAMA Intern Med*, 177(4), 500-507.
 77. **Beddhu S**, Wei G, Chen X, Boucher RE, Kiani R, Raj D, Chonchol M, Greene T, Murtaugh MA (04/18/2017). Associations of Dietary Protein and Energy Intakes with Protein-Energy Wasting Syndrome in Hemodialysis Patients. *KI Rep*, 2(5), 821-830
 78. Bress AP, Kramer H, Khatib R, **Beddhu S**, Cheung AK, Hess R, Bansal VK, Cao G, Yee J, Moran AE, Durazo-Arvizu R, Muntner P, Cooper RS (04/25/2017). Potential Deaths Averted and Serious Adverse Events Incurred from Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections from NHANES (National Health and Nutrition Examination Survey). *Circulation*, 135(17), 1617-1628.
 79. **Beddhu S**, Chen X, Wei G, Raj D, Raphael KL, Boucher R, Chonchol MB, Murtaugh MA, Greene T (05/01/2017). Associations of Protein-Energy Wasting Syndrome Criteria with Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States. *KI Rep*, 2(3), 390-399.
 80. Kalantar-Zadeh K, Crowley ST, **Beddhu S**, Chen JLT, Daugirdas JT, Goldfarb DS, Jin A, Kovesdy CP, Leehey DJ, Moradi H, Navaneethan SD, Norris KC, Obi Y, O'Hare A, Shafi T, Streja E, Unruh ML, Vachharajani TJ, Weisbord S, Rhee CM (05/01/2017). Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease. *Semin Dial*, 30(3), 251-261.
 81. Muralidharan J, Ramezani A, Hubal M, Knoblach S, Shrivastav S, Karandish S, Scott R, Maxwell N, Ozturk S, **Beddhu S**, Kopp JB, Raj DS (06/01/2017). Extracellular microRNA signature in chronic kidney disease. *Am J Physiol Renal Physiol*, 312(6), F982-F991.
 82. Raphael KL, Carroll DJ, Murray J, Greene T, **Beddhu S** (08/01/2017). Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease. *J Am Soc Nephrol*, 28(8), 2483-2490.
 83. Bress AP, King JB, Kreider KE, **Beddhu S**, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord

- J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V, SPRINT Research Group (08/09/2017). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. *Diabetes Care*, 40(10), 1401-1408.
84. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Group (08/24/2017). Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. *N Engl J Med*, 344(8), 733-744.
 85. Bress AP, Bellows BK, King JB, Hess R, **Beddhu S**, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negrón N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE, SPRINT Research Group (08/24/2017). Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*, 377(8), 745-755.
 86. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, **Beddhu S**, Bhatt U, Chang Ti, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J, SPRINT Research Group (09/01/2017). Effects of Intensive BP Control in CKD. *J Am Soc Nephrol*, 28(9), 2812-2823.
 87. **Beddhu S**, Rocco M, Toto R, Craven TE, Greene T, Bhatt U, Cheung AK, Cohen D, Freedman BI, Hawfield AT, Killeen AA, Kimmell PL, Lash J, Papademetriou V, Rahman M, Rastogi A, Servilla K, Townsend RR, Wall B, Whelton PK, SPRINT Research Group (09/19/2017). Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of Randomized Trial. *Ann Intern Med*, 167(6), 375-383.
 88. **Beddhu S**, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, Wei G, Campbell RC, Conroy M, Freedman BI, Haley W, Horwitz E, Kitzman D, Lash J, Papademetriou V, Pisoni R, Riessen E, Rosendorff C, Watnick SG, Whittle J, Whelton PK, SPRINT Research Group (01/09/2018). Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared with Standard Blood Pressure Control. *Circulation*, 137(2), 134.
 89. Kramer H, Boucher RE, Leehey D, Fried L, Wei G, Greene T, Rosas SE, Cooper R, Cao G, **Beddhu S** (02/07/2018). Increasing Mortality in Adults with Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria. *Diabetes Care*, Apr;41(4):775-781. doi: 10.2337/dc17-1954. Epub 2018 Feb 7. PMID: 29436384
 90. Raphael KL, Gilligan S, Hostettler TH, Greene T, **Beddhu S** (02/07/2018). Association between Urine Ammonium and Urine TGF- β 1 in CKD. *Clin J Am Soc Nephrol*, 13(2), 223-230.
 91. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, **Beddhu S**, Kimmell PL, Reboussin DM, Chertow GM, SPRINT Research Group (03/07/2018). Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). *Am J Kidney Dis*, 71(3), 352-361.
 92. Johnson KC, Whelton PK, Cushman WC, Cutler JA, Evans GW, Snyder JK, Ambrosius WT, **Beddhu S**, Cheung AK, Fine LJ, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Oparil S, Wright JT (03/12/2018). Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). *Hypertension*, 71(4).
 93. Kulikowski E, Halliday C, Johansson J, Sweeney M, Lebioda K, Wong N, Haarhaus M, Brandenburg V, **Beddhu S**, Tonelli M, Zoccali C, Kalantar-Zadeh K (03/16/2018). Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline

- Phosphatase Profile in Patients with Chronic Kidney Disease. *Kidney Blood Press Res*, 43(2), 449-457.
94. Tian M, Tang L, Wu Y, **Beddhu S**, Huang Y. Adiponectin attenuates kidney injury and fibrosis in deoxycorticosterone acetate-salt and angiotensin II induced CKD mice. *Am J Physiol Renal Physiol*. 2018 Jun 6. doi: 10.1152/ajprenal.00137.2018. [Epub ahead of print] PMID: 29873514
Shapiro BP, Ambrosius WT, Blackshear JL, Cushman WC, Whelton PK, Oparil S, **Beddhu S**, Dwyer JP, Gren LH, Kostis WJ, Lioudis M, Pisoni R, Rosendorff C, Haley WE; SPRINT Research Group Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). *Hypertension*. 2018 Jun;71(6):1064-1074. doi: 10.1161/HYPERTENSIONAHA.117.10646. Epub 2018 Apr 30. PMID: 29712745.
 95. **Beddhu S**, Greene T, Boucher R, Cushman WC, Wei G, Stoddard G, Ix JH, Chonchol M, Kramer H, Cheung AK, Kimmel PL, Whelton PK, Chertow GM. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. *Lancet Diabetes Endocrinol*. 2018 Jul;6(7):555-563. doi: 10.1016/S2213-8587(18)30099-8. PMID:29685860.
 96. **Beddhu S**, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, Zhang C, Kramer H, Bress AP, Kimmel PL, Oparil S, Lewis C, Rahman R and Cushman WC. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in persons with type 2 diabetes on standard glycemic control and in persons without diabetes: reconciling results from ACCORD BP and SPRINT. *J Am Heart Assoc*. 2018 Sep 18;7(18): e009326. doi: 10.1161/JAHA.118.009326.
 97. Supiano MA, Lovato L, Ambrosius WT, Bates J, **Beddhu S**, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, Weiner DE, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol M. Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. *PLoS One*. 2018 Sep 26;13(9): e0203305. doi: 10.1371/journal.pone.0203305. eCollection 2018. PubMed PMID: 30256784; PubMed Central PMCID: PMC6157848.
 98. Bansal S, Wei G, Boucher RE, **Beddhu S**. Self-reported Intentional Weight Loss and Risk of Death in Moderate Chronic Kidney Disease in the United States. *J Ren Nutr*. 2018 Nov;28(6):422-427. doi: 10.1053/j.jrn.2018.04.001. Epub 2018 Aug 1. PubMed PMID: 30077396
Hall IE, Shaaban A, Wei G, Sikora MB, Bouriya H, **Beddhu S**, Shihab F. Baseline living-donor kidney volume and function associate with 1-year post-nephrectomy kidney function. *Clin Transplant*. 2019 Mar;33(3): e13485. doi: 10.1111/ctr.13485. Epub 2019 Feb 12. PubMed PMID: 30689244; PubMed Central PMCID: PMC6487946
 99. Amdur RL, Feldman HI, Dominic EA, Anderson AH, **Beddhu S**, Rahman M, Wolf M, Reilly M, Ojo A, Townsend RR, Go AS, He J, Xie D, Thompson S, Budoff M, Kasner S, Kimmel PL, Kusek JW, Raj DS; CRIC Study Investigators. Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients with CKD: Findings from the CRIC Study. *Am J Kidney Dis*. 2019 Mar;73(3):344-353. doi: 10.1053/j.ajkd.2018.09.012. Epub 2018 Dec 10. PubMed PMID: 30545708.
 100. Kramer HJ, Townsend RR, Griffin K, Flynn JT, Weiner DE, Rocco MV, Choi MJ, Weir MR, Chang TI, Agarwal R, **Beddhu S**. KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. *Am J Kidney Dis*. 2019 Apr;73(4):437-458. doi: 10.1053/j.ajkd.2019.01.007. PubMed PMID: 30905361.
 101. Rathi N, Whelton PK, Chertow GM, Cushman WC, Cheung AK, Wei G, Boucher R, Kimmel PL, Bress A, Kramer HJ, Al-Marji C, Greene T, **Beddhu S**. Influence of prediabetes on the effects of intensive systolic blood pressure control on kidney events. *Am J Hypertens*. 2019 Jun 29. pii: hpz105. doi: 10.1093/ajh/hpz105. [Epub

- ahead of print] PubMed PMID: 31257407.
102. **Beddhu S**, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Cambell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK and Greene T. Implications of early decline in estimated glomerular filtration rate due to intensive blood pressure control for cardiovascular outcomes in SPRINT. *J Am Soc Nephrol*. 2019 Aug;30(8):1523-1533.
 103. Dobre M, Pajewski NM, **Beddhu S**, Chonchol M, Hostetter TH, Li P, Rahman M, Servilla K, Weiner DE, Wright JT, Raphael KL; SPRINT Research Group. Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial. *Nephrol Dial Transplant*. 2019 Aug 14;gfz149. doi: 10.1093/ndt/gfz149. Epub ahead of print. PMID: 32163578.
 104. Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Halliday C, Lebioda K, Wong N, Brandenburg V, **Beddhu S**, Tonelli M, Zoccali C, Kalantar-Zadeh K. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. *Atherosclerosis*. 2019 Sep 17;290:59-65. doi:10.1016/j.atherosclerosis.2019.09.002. [Epub ahead of print] PubMed PMID: 31568963.
 105. Drawz PE, **Beddhu S**, Kramer HJ, Rakotz M, Rocco MV, Whelton PK. Blood Pressure Measurement: A KDOQI Perspective. *Am J Kidney Dis*. 2020 Mar;75(3):426-434. doi: 10.1053/j.ajkd.2019.08.030. Epub 2019 Dec 18. PMID: 31864820.
 106. Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, **Beddhu S**. Sodium Bicarbonate Supplementation and Urinary TGF- β 1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. *Clin J Am Soc Nephrol*. 2020 Feb 7;15(2):200-208. doi: 10.2215/CJN.06600619. Epub 2020 Jan 23. PMID: 31974286; PMCID: PMC7015087.
 107. **Beddhu S**, Whelton PK. Early Decline in Kidney Function With Intensive Systolic Blood Pressure Lowering: Does It Matter? *Hypertension*. 2020 May;75(5):1163-1164. doi: 10.1161/HYPERTENSIONAHA.120.14784. Epub 2020 Mar 30. PMID: 32223378.
 108. Dobre M, Pajewski NM, **Beddhu S**, Chonchol M, Hostetter TH, Li P, Rahman M, Servilla K, Weiner DE, Wright JT, Raphael KL; SPRINT Research Group. Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial. *Nephrol Dial Transplant*. 2020 Aug 1;35(8):1377-1384. doi: 10.1093/ndt/gfz149. PMID: 32163578.
 109. Chang AR, Kramer H, Wei G, Boucher R, Grams ME, Berlowitz D, Bhatt U, Cohen DL, Drawz P, Punzi H, Freedman BI, Haley W, Hawfield A, Horwitz E, McLouth C, Morisky D, Papademetriou V, Rocco MV, Wall B, Weiner DE, Zias A, **Beddhu S**; SPRINT Research Group. Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT. *Clin J Am Soc Nephrol*. 2020 Aug 7;15(8):1121-1128. doi: 10.2215/CJN.12371019. Epub 2020 Jul 15. PMID: 32669306.
 110. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, Ambrosius W, Chertow GM, **Beddhu S**. The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. *Diabetes Care*. 2020 Aug;43(8):1878-1884. doi: 10.2337/dc19-2047. Epub 2020 May 4. PMID: 32366577.
 111. Gupta A, Kennedy K, Perales-Puchalt J, Drew D, **Beddhu S**, Sarnak M, Burns J; Alzheimer's Disease Neuroimaging Initiative. Mild-moderate CKD is not associated with cognitive impairment in older adults in the Alzheimer's Disease Neuroimaging Initiative cohort. *PLoS One*. 2020 Oct 9;15(10):e0239871. doi: 10.1371/journal.pone.0239871. eCollection 2020. PMID: 33036021.
 112. Gupta A, Perdomo S, Billinger S, **Beddhu S**, Burns J, Gronseth G. Treatment of hypertension reduces cognitive decline in older adults: a systematic review and meta-analysis. *BMJ Open*. 2020

- Nov 17;10(11):e038971. doi: 10.1136/bmjopen-2020-038971.PMID: 33203630.
113. Rapp SR, Gaussoin SA, Sachs BC, Chelune G, Supiano MA, Lerner AJ, Wadley VG, Wilson VM, Fine LJ, Whittle JC, Auchus AP, **Beddhu S**, Berlowitz DR, Bress AP, Johnson KC, Krousel-Wood M, Martindale-Adams J, Miller EC, Rifkin DE, Snyder JK, Tamariz L, Wolfgram DF, Cleveland ML, Yang M, Nichols LO, Bryan RN, Reboussin DM, Williamson JD, Pajewski NM; SPRINT Research Group. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial. *Lancet Neurol.* 2020 Nov;19(11):899-907. doi: 10.1016/S1474-4422(20)30319-7.PMID: 33098800.
 114. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med.* 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.PMID: 33264825.
 115. Edmonston DL, Isakova T, Dember LM, Brunelli S, Young A, Brosch R, **Beddhu S**, Chakraborty H, Wolf M. Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. *Am J Kidney Dis.* 2021 Jun;77(6):920-930.e1. doi: 10.1053/j.ajkd.2020.10.008. Epub 2020 Dec 3.PMID: 33279558
 116. Kalantar-Zadeh K, **Beddhu S**, Kovesdy CP, Kramer HJ, Fouque D. Biologically plausible trends suggesting that a low-protein diet may enhance the effect of flozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria. *Diabetes Obes Metab.* 2021 Aug 13. doi: 10.1111/dom.14524. PMID: 34387935.
 117. Koppe L, **Beddhu S**, Chauveau P, Kovesdy CP, Mafra D, Joshi S, Kalantar-Zadeh K, Fouque D. A call for a better understanding of the role of dietary amino acids and post-translational protein modifications of the microbiome in the progression of CKD. *Nephrol Dial Transplant.* 2021 Jul 23;36(8):1357-1360. doi: 10.1093/ndt/gfab033.PMID: 33576406
 118. SPRINT Research Group, Lewis CE, Fine LJ, **Beddhu S**, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med.* 2021 May 20;384(20):1921-1930. doi: 10.1056/NEJMoa1901281.PMID: 34010531.
 119. Nasrallah IM, Gaussoin SA, Pomponio R, Dolui S, Erus G, Wright CB, Launer LJ, Detre JA, Wolk DA, Davatzikos C, Williamson JD, Pajewski NM, Bryan RN; SPRINT Research Group. Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. *JAMA Neurol.* 2021 May 1;78(5):568-577. doi: 10.1001/jamaneurol.2021.0178.PMID: 33683313.
 120. Lyden K, Boucher R, Wei G, Zhou N, Christensen J, Chertow GM, Greene T, **Beddhu S**. Targeting Sedentary Behavior in CKD: A Pilot and Feasibility Randomized Controlled Trial. *Clin J Am Soc Nephrol.* 2021 May 8;16(5):717-726. doi: 10.2215/CJN.12300720. Epub 2021 Apr 22.PMID: 33888536.
 121. Kalantar-Zadeh K, McCullough PA, Agarwal SK, **Beddhu S**, Boaz M, Bruchfeld A, Chauveau P, Chen J, de Sequera P, Gedney N, Golper TA, Gupta M, Harris T, Hartwell L, Liakopoulos V, Kopple JD, Kovesdy CP, Macdougall IC, Mann JFE, Molony D, Norris KC, Perlmutter J, Rhee CM, Riella LV, Weisbord SD, Zoccali C, Goldsmith D. Nomenclature in nephrology: preserving 'renal' and 'nephro' in the glossary of kidney health and disease. *J Nephrol.* 2021 Jun;34(3):639-648. doi: 10.1007/s40620-021-01011-3. Epub 2021 Mar 13.PMID: 33713333.
 122. **Beddhu S**, Boucher RE, Sun J, Balu N, Chonchol M, Navaneethan S, Chertow GM, Townsend R, Haley W, Cheung AK, Conroy MB, Raj DS, Xu D, George T, Yunis R, Wei G, Canton G, Bates J, Chen J, Papademetriou V, Punzi H, Wiggers A, Wright JT, Greene T, Yuan C. Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. *BMC Nephrol.* 2021 Feb 24;22(1):69. doi: 10.1186/s12882-021-02260-x.PMID: 33627066.

123. Agarwal A, Wei G, Boucher R, Ahmed F, **Beddhu S**. Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index. *Nephrology (Carlton)*. 2021 Apr;26(4):303-311. doi: 10.1111/nep.13857. Epub 2021 Feb 23. PMID: 33538091.
124. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, **Beddhu S**, Cheung AK, Xian W, Weintraub WS, Bress AP. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. *PLoS One*. 2021 Apr 23;16(4):e0248080. doi: 10.1371/journal.pone.0248080. eCollection 2021. PMID: 33891615.
125. Kalantar-Zadeh K, **Beddhu S**, Kovesdy CP, Kramer HJ, Fouque D. Biologically plausible trends suggesting that a low-protein diet may enhance the effect of fozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria. *Diabetes Obes Metab*. 2021 Dec;23(12):2825-2826. doi: 10.1111/dom.14524. Epub 2021 Aug 31. PMID: 34387935.
126. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl J Med*. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. PMID: 34449181.
127. Kurella Tamura M, Gaussoin S, Pajewski NM, Zaharchuk G, Freedman BI, Rapp SR, Auchus AP, Haley WE, Oparil S, Kendrick J, Roumie CL, **Beddhu S**, Cheung AK, Williamson JD, Detre JA, Dolui S, Bryan RN, Nasrallah IM; SPRINT Research Group. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. *Am J Kidney Dis*. 2021 Sep 17:S0272-6386(21)00877-5. doi: 10.1053/j.ajkd.2021.07.024. Epub ahead of print. PMID: 34543687; PMCID: PMC8926938.
128. Wright JT Jr, Whelton PK, Johnson KC, Snyder JK, Reboussin DM, Cushman WC, Williamson JD, Pajewski NM, Cheung AK, Lewis CE, Oparil S, Rocco MV, **Beddhu S**, Fine LJ, Cutler JA, Ambrosius WT, Rahman M, Still CH, Chen Z, Tatsuoka C; SPRINT Research Group. SPRINT Revisited: Updated Results and Implications. *Hypertension*. 2021 Dec;78(6):1701-1710. doi: 10.1161/HYPERTENSIONAHA.121.17682. Epub 2021 Nov 10. PMID: 34757768; PMCID: PMC8824314.
129. Drawz PE, **Beddhu S**, Bignall ONR 2nd, Cohen JB, Flynn JT, Ku E, Rahman M, Thomas G, Weir MR, Whelton PK. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. *Am J Kidney Dis*. 2022 Mar;79(3):311-327. doi: 10.1053/j.ajkd.2021.09.013. Epub 2022 Jan 18. PMID: 35063302.
130. Shihab S, Boucher RE, Abraham N, Wei G, **Beddhu S**. Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Systolic Blood Pressure Lowering on the Risk of Stroke. *Hypertension*. 2022 Apr;79(4):785-793. doi: 10.1161/HYPERTENSIONAHA.121.18172. Epub 2022 Feb 4. PMID: 35114798; PMCID: PMC8917090.
131. Grube D, Wei G, Boucher R, Abraham N, Zhou N, Gonce V, Carle J, Simmons DL, **Beddhu S**. Insulin use in chronic kidney disease and the risk of hypoglycemic events. *BMC Nephrol*. 2022 Feb 21;23(1):73. doi: 10.1186/s12882-022-02687-w. PMID: 35189851; PMCID: PMC8862360.
132. Kurella Tamura M, Gaussoin S, Pajewski NM, Zaharchuk G, Freedman BI, Rapp SR, Auchus AP, Haley WE, Oparil S, Kendrick J, Roumie CL, **Beddhu S**, Cheung AK, Williamson JD, Detre JA, Dolui S, Bryan RN, Nasrallah IM; SPRINT Research Group.

- Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. *Am J Kidney Dis*. 2022 May;79(5):677-687.e1. doi: 10.1053/j.ajkd.2021.07.024. Epub 2021 Sep 17. PMID: 34543687; PMCID: PMC8926938.
133. Drawz PE, Rai NK, Lenoir KM, Suarez M, Powell JR, Raj DS, **Beddhu S**, Agarwal AK, Soman S, Whelton PK, Lash J, Rahbari-Oskoui FF, Dobre M, Parkulo MA, Rocco MV, McWilliams A, Dwyer JP, Thomas G, Rahman M, Oparil S, Horwitz E, Pajewski NM, Ishani A. Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. *Kidney360*. 2022 May 10;3(7):1253-1262. doi: 10.34067/KID.0001572022. PMID: 35919535; PMCID: PMC9337898.
 134. Azim A, Murray J, **Beddhu S**, Raphael KL. Urinary Sulfate, Kidney Failure, and Death in CKD: The African American Study of Kidney Disease and Hypertension. *Kidney360*. 2022 Apr 27;3(7):1183-1190. doi: 10.34067/KID.0000322022. PMID: 35919537; PMCID: PMC9337883.
 135. Gupta A, Boucher R, Wei G, Gronseth G, Parks A, **Beddhu S**. Influence of Baseline Diastolic Blood Pressure on the Effects of Systolic Blood Pressure Lowering on Cognitive Function in Type 2 Diabetes Mellitus. *Am J Hypertens*. 2022 Oct 13;hpac118. doi: 10.1093/ajh/hpac118. Epub ahead of print. PMID: 36227718.
 136. Kim DH, Tatsuoka C, Chen Z, Wright JT Jr, Odden MC, **Beddhu S**, Bellows BK, Bress A, Carson T, Cushman WC, Johnson KC, Morisky DE, Punzi H, Tamariz L, Yang S, Wei LJ. Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial. *J Gen Intern Med*. 2022 Nov;37(15):3797-3804. doi: 10.1007/s11606-022-07753-5. Epub 2022 Aug 9. PMID: 35945470; PMCID: PMC9640478.

REVIEW ARTICLES

1. Logar CM, Herzog CA, **Beddhu S** (2003). Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. [Review]. *Am J Med Sci*, 325(4), 214-27.
2. **Beddhu S** (2004). The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease. [Review]. *Semin Dial*, 17(3), 229-32.
3. Kwan BC, Kronenberg F, **Beddhu S**, Cheung AK (2007). Lipoprotein metabolism and lipid management in chronic kidney disease. [Review]. *J Am Soc Nephrol*, 18(4), 1246-61.
4. Kwan BC, **Beddhu S** (2007). A story half untold: adiposity, adipokines and outcomes in dialysis population. [Review]. *Semin Dial*, 20(6), 493-7.
5. Kramer H, Tuttle KR, Leehey D, Luke A, Durazo-Arvizu R, Shoham D, Cooper R, **Beddhu S** (2009). Obesity management in adults with CKD. [Review]. *Am J Kidney Dis*, 53(1), 151-65.
6. Filipowicz R, **Beddhu S** (2013). Optimal nutrition for predialysis chronic kidney disease. [Review]. *Adv Chronic Kidney Dis*, 20(2), 175-80.
7. Filipowicz R, **Beddhu S** (2013). Optimal nutrition for predialysis chronic kidney disease. [Review]. *Adv Chronic Kidney Dis*, 20(2), 175-80.
8. **Beddhu S**, Abraham J (2013). Risk Factor Paradox in CKD and ESRD: Does a Healthy Lifestyle Matter? [Review]. *Clin J Am Soc Nephrol*, 8(4), 515-7.
9. Zaman T, Filipowicz R, **Beddhu S** (2013). Implications and importance of skeletal muscle mass in estimating glomerular filtration rate at dialysis initiation. [Review]. *J Ren Nutr*, 23(3), 233-6.

BOOK CHAPTERS

1. Kwan BCH, **Beddhu S** (11/01/2005). Adiposity in Kidney Disease in Adipose tissue and adipokines

- in health and disease. In Fantuzzi G and Mazzone T. (Eds.). Humana Press.
2. **Beddhu S** (01/01/2008). Outcomes in ESRD. Primer of Kidney Diseases.
 3. **Beddhu S** (2009). Nutrition and Chronic Kidney Disease. In Bales CW, Ritchie CS (Eds.), *Handbook of Clinical Nutrition and Aging* (2nd Edition, pp. 403-16). New York: Humana Press.
 4. **Beddhu S** (2010). Cardiovascular Disease: Coronary Artery Disease and Coronary Artery Calcification in Cardiorenal Syndrome. In Berbari AD and Mancia G (Ed.). Springer Press.
 5. Beddhu, S. and Abrahama, J (04/01/2014). Adiposity and Kidney Disease. In Fantuzzi, Giamila, Braunschweig, Carol (Eds.), *Adipose Tissue and Adipokines in Health and Disease* (Second Edition, pp. 315-324). Humana Press.
 6. Chen X, **Beddhu S** (2015). Nutrition and Chronic Kidney Disease. In Bales CW, Locher JL, Saltzman E (Eds.), *Handbook of Clinical Nutrition and Aging* (3rd Edition, pp. 261-72). New York: Humana Press.
 7. **Beddhu S** (2015). Nutrition and Chronic Kidney Disease. In Bales CW, Ritchie CS (Eds.), *Handbook of Clinical Nutrition and Aging* (3rd Edition). New York: Humana Press

OTHER (Commentary/Letters/Editorials/)

Editorials

1. **Beddhu S**, Abraham J (2013). Risk factor paradox in CKD and ESRD: does a healthy lifestyle matter? *Clin J Am Soc Nephrol*, 8(4), 515-7.
2. Chertow GM, **Beddhu S**. Modification of eGFR-Based CKD Definitions: Perfect, or Enemy of the Good? *J Am Soc Nephrol*. 2019 Oct;30(10):1807-1809. doi: 10.1681/ASN.2019070743. Epub 2019 Sep 10. PubMed PMID: 31506290; PubMed Central PMCID: PMC6779365.
3. **Beddhu S**, Whelton PK. Early Decline in Kidney Function With Intensive Systolic Blood Pressure Lowering: Does It Matter? *Hypertension*. 2020 May;75(5):1163-1164. doi: 10.1161/HYPERTENSIONAHA.120.14784. Epub 2020 Mar 30. PMID: 32223378.
4. Hartsell SE, **Beddhu S**. Diastolic Blood Pressure and the J-Curve-Causal Effect or Confounding? *JAMA Netw Open*. 2021 Oct 1;4(10):e2130031. doi: 10.1001/jamanetworkopen.2021.30031. PMID: 34668952; PMCID: PMC8967343.
5. Anand S, Chertow GM, **Beddhu S**. Obesity and Incident Kidney Disease: Busting the Myth of Metabolically Healthy Obesity. *Am J Kidney Dis*. 2022 Jan;79(1):7-8. doi: 10.1053/j.ajkd.2021.08.008. Epub 2021 Oct 30. PMID: 34728104; PMCID: PMC8967374.
6. Drawz PE, **Beddhu S**, Bignall ONR 2nd, Cohen JB, Flynn JT, Ku E, Rahman M, Thomas G, Weir MR, Whelton PK. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. *Am J Kidney Dis*. 2022 Mar;79(3):311-327. doi: 10.1053/j.ajkd.2021.09.013. Epub 2022 Jan 18. PMID: 35063302.
7. Friedman AN, Schauer PR, **Beddhu S**, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. *Am J Kidney Dis*. 2022 Dec;80(6):783-793. doi: 10.1053/j.ajkd.2022.06.007. Epub 2022 Oct 21. PMID: 36280397.

Letters

1. **Beddhu S** (2003). Say "no" and comorbidity [Letter to the editor]. *Am J Kidney Dis*, 42(2), 429-30; author reply 429.
2. **Beddhu S**, Pappas LM, Ramkumar N, Samore MH (2005). Body mass index and survival in incident dialysis patients: the answer depends on the question [Letter to the editor]. *Am J Clin Nutr*, 81(2), 534-

- 6; author reply 536.
3. **Beddhu S**, Ramkumar N, Samore MH (2005). The paradox of the "body mass index paradox" in dialysis patients: associations of adiposity with inflammation [Letter to the editor]. *Am J Clin Nutr*, 82(4), 909-10; author reply 910-11.
 4. **Beddhu S** (2006). If fat is good, muscle is better [Letter to the editor]. *Am J Kidney Dis*, 47(1), 193; author reply 193-4.
 5. **Beddhu S**, Chertow GM, Cheung AK, Cushman WC, Greene T, Wei G, Boucher R, Whelton PK; SPRINT Research Group. Response by **Beddhu et al** to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared with Standard Blood Pressure Control". *Circulation*. 2018 Jun 12;137(24):2668-2669.
doi:10.1161/CIRCULATIONAHA.118.034738. PMID:29891628

RECENTLY PUBLISHED ABSTRACTS (from 2015)

- 1 **Beddhu S**, Boucher RE, Agarwal A, Bjordhal TS, Simmons DL, Fried LF, Navaneethan SD (10/26/2018). *Meta-Analysis on the Effects of Intensive (INT) Blood Pressure (BP) Control on Incident CKD and ESRD* [Abstract]. *American Society of Nephrology. Oct 23 – Oct 28, 2018 San Diego, CA.*
- 2 **Beddhu S**, Kimmel PL, Chertow GM, Cheung AK, Wei G, Boucher RE, Chonchol M, Freedman BI, Ix JH, Rocco MV, Whelton PK, Greene T (Oct/26/2018). *Associations of Early Decline in eGFR with Cardiovascular Disease (CVD) Events in the Systolic Blood Pressure Intervention Trial (SPRINT)* [Abstract]. *American Society of Nephrology. Oct 23 – Oct 28, 2018 San Diego, CA.*
3. Rathi N, Wei G, Boucher RE, Greene T, **Beddhu S** (10/26/2018). *Influence of Pre-Diabetes Status on the Effects of Intensive Systolic Blood Pressure (SBP) Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT)* [Abstract]. *American Society of Nephrology. Oct 23 – Oct 28, 2018 San Diego, CA.*
4. Kalami LR, Greene T, Guo W, Cheung AK, **Beddhu S** (10/27/2018). *Effect of Oral Sodium Bicarbonate on Urine TGF- β 1 in Non-Acidotic Diabetic Kidney Disease (DKD)* [Abstract]. *American Society of Nephrology. Oct 23 – Oct 28, 2018 San Diego, CA.*
5. Wolf M, Dember LM, **Beddhu S**, Block GA, Brunelli SM, Weiner DE, Isakova T (10/25/2018). *HiLo: A Pragmatic Trial of Phosphate Management in ESRD* [Abstract]. *American Society of Nephrology. Oct 23 – Oct 28, 2018 San Diego, CA.*
6. Grube D, Boucher RE, Zhou N, Wei G, Simmons DL, Cheung AK, Greene T, **Beddhu S** (11/07/2019). *Advanced CKD is Associated with Higher and Not Lower Insulin Use* [Abstract]. *American Society of Nephrology. Nov 5 – Nov 10, 2019 Washington, DC.*
7. Zhou N, Boucher RE, Wei G, Caamano A, Greene T, **Beddhu S** (11/07/2019). *Hypercatabolism, Body Composition, and Physical Function in Advanced CKD* [Abstract]. *American Society of Nephrology. Nov 5 – Nov 10, 2019 Washington, DC.*
8. Gupta A, Kennedy KF, **Beddhu S**, Burns JM (11/07/2019). *Renal Function Does Not Have a Graded Inverse Association with Cognition in the Elderly* [Abstract]. *American Society of Nephrology. Nov 5 – Nov 10, 2019 Washington, DC*
9. Gupta A, Perdomo S, **Beddhu S**, Billinger S, Burns JM, Gronseth G (11/07/2019). *Blood Pressure Lowering and Cognition: A Systematic Review and Meta-Analysis* [Abstract]. *American Society of Nephrology. Nov 5 – Nov 10, 2019 Washington, DC*
10. Gupta A, Boucher RE, Greene T, Parks A, Wei G, **Beddhu S** (11/07/2019). *Baseline Diastolic Blood Pressure Does Not Influence the Effect of Systolic Blood Pressure Lowering on Cognition in Type 2 Diabetes Mellitus* [Abstract]. *American Society of Nephrology. Nov 5 – Nov 10, 2019 Washington, DC*
11. Hartsell SE, Boucher RE, Navaneethan SD, Chertow GM, Chonchol M, Haley WE, Cheung AK, Wright JT, Greene T, Townsend RR, Balu N, Xu D, Sun J, Canton G, Yuan C, **Beddhu S** (11/07/2019). *CKD, Atherosclerotic Plaque Characteristics on Carotid Magnetic Resonance*

- Imaging, and Cardiovascular Outcomes* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
12. Haarhaus M, Ray KK, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Khan A, Halliday C, Lebioda KE, Wong NC, Winblad B, Zetterberg H, Brandenburg V, **Beddhu S**, Tonelli M, Zoccali C, Kalantar-Zadeh K (11/08/2019). *Association of Serum Alkaline Phosphatase with CKD and Cognitive Function in Patients with Diabetes and Acute Coronary Syndrome* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
 13. Ilkun O, Greene T, Wei G, Boucher RE, Cheung AK, Chertow GM, Ambrosius WT, Whelton PK, **Beddhu S** (11/08/2019). *The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes in Type 2 Diabetes Mellitus* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
 14. Ilkun O, Greene T, Wei G, Boucher RE, Cheung AK, Chertow GM, Ambrosius WT, Whelton PK, **Beddhu S** (11/08/2019). *The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on All-Cause Mortality in Type 2 Diabetes Mellitus* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
 15. Chaturvedula CK, Kramer HJ, Wei G, Boucher RE, Kalipatnapu SMP, **Beddhu S** (11/08/2019). *Heart Failure Risk with Intensive Systolic Blood Pressure (SBP) Lowering Does Not Differ by Albuminuria Status in Diabetes* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
 16. Agarwal A, Wei G, Boucher RE, Greene T, **Beddhu S** (11/08/2019). *Modification of Effect of Intensive Blood Pressure Lowering on Cardiovascular (CV) Outcomes by Baseline Body Mass Index (BMI)* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
 17. Haarhaus M, Johansson JO, Sweeney M, Kulikowski E, Wong NC, Halliday C, Khan A, Lebioda KE, Brandenburg V, **Beddhu S**, Tonelli M, Zoccali C, Kalantar-Zadeh K (11/08/2019). *Apabetalone Lowers Serum Alkaline Phosphatase in CVD Patients with and without CKD and Improves Cardiovascular Risk* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
 18. Rathi N, Boucher RE, Wei G, Greene T, Hartsell SE, Gribbin KH, Bair B, Eleazer GP, **Beddhu S** (11/09/2019). *Rural vs. Urban Residence and Survival on Chronic Maintenance Dialysis in US Veterans* [Abstract]. *American Society of Nephrology*. Nov 5 – Nov 10, 2019 Washington, DC
 19. Boucher RE, Wei G, Greene T, **Beddhu S**. A Pilot and Feasibility Randomized Clinical Trial Targeting Sedentary Behavior in CKD: Sit Less, Interact and Move More (SLIMM) Study [Abstract]. *American Society of Nephrology*. Oct 22 – Oct 25, 2020 On-Demand.
 20. Daulton G, Wei G, Boucher RE, **Beddhu S**. *Advanced CKD Augments the Risk of Hypoglycemia with Insulin Use*. [Abstract]. *American Society of Nephrology*. Oct 22 – Oct 25, 2020 On-Demand.
 21. Shweta B, Shen J, Wei G, Boucher RE, Chertow GM, Whelton PK, Cheung AK, **Beddhu S**. *Associations of Diuretic Use with Cardiovascular Events and All-Cause Mortality in the Systolic BP Intervention Trial (SPRINT)* [Abstract]. *American Society of Nephrology*. Oct 22 – Oct 25, 2020 On-Demand.
 22. Boucher RE, Wei G, Ilkun O, **Beddhu S**. *The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Incident Strokes in the SPS3 Trial* [Abstract]. *American Society of Nephrology*. Oct 22 – Oct 25, 2020 On-Demand.
 23. Ilkun O, Wei G, Boucher RE, **Beddhu S**. *The Influence of Baseline Diastolic Blood Pressure on the Effects of Blood Pressure Lowering on Death and ESKD Outcome* [Abstract]. *American Society of Nephrology*. Oct 22 – Oct 25, 2020 On-Demand.
 24. **Beddhu S**, Shen J, Chertow GM, Whelton PK, Wei G, Boucher RE, Cheung AK, Greene T. *Early GFR Decline with Intensive BP Lowering and the Risk of Death and ESKD: Mediation Analysis of AASK Study* [Abstract]. *American Society of Nephrology*. Oct 22 – Oct 25, 2020 On-Demand.
 25. Sammons S, Wei G, Boucher RE, Carle J, Gonce V, Hartsell SE, Abraham N, **Beddhu S**. *Racial*

- Disparities in Progression to ESRD and Mortality in Rural vs. Urban Veteran.* [Abstract]. *American Society of Nephrology.* Nov 04, 2021. On Demand.
- 25 Hartsell SE, Guo W, Boucher RE, **Beddhu S.** Role of Hypertension in the Risk of Heart Failure in CKD. [Abstract]. *American Society of Nephrology.* Nov 04, 2021. On Demand.
- 26 **Beddhu S,** Boucher RE, Gonce V, Hartsell SE, Abraham N, Guo W. Insulin Use and CKD Are Risk Factors for Mild Cognitive Impairment (MCI) or Dementia in Persons with Type 2 Diabetes.]. *American Society of Nephrology.* Nov 04, 2021. On Demand.
27. Gonce V, Wei G, Boucher RE, Carle J, Hartsell SE, Abraham N, **Beddhu S.** African Americans Have Lower COVID-19 Mortality Risk Than Caucasians in CKD.]. *American Society of Nephrology.* Nov 04, 2021. On Demand.
28. Hartsell SE, Ye, X, Sarwal A, Boucher RE, Wei G, **Beddhu S.** Heart Failure: A Risk Factor for Progression to ESKD. [Abstract]. *American Society of Nephrology.* Nov 3-5, 2022
Sarwal A, Boucher RE, Hartsell SE, Ye, X, , Wei G, **Beddhu S.** The Association of Hyponatremia With Cognitive Function and All-Cause Mortality: A Post Hoc Analysis of the Systolic Blood Pressure Intervention Trial, [Abstract]. *American Society of Nephrology.* Nov 3-5, 2022

ORAL PRESENTATIONS

Meeting Presentations

- 2000 Hypoalbuminemia Represents an Atherosclerotic Milieu in Hemodialysis Patients. **Beddhu S,** Kaysen GA, Yan G, Sarnak M, Agodoa L, Cheung AK and the HEMO study group. American Society of Nephrology Annual Meeting, Toronto, ON.
- 2005 Does Inflammation Explain the Inverse Associations of Body Mass Index (BMI) and Serum Creatinine (Scr) with Cardiovascular (CV) and All-Cause (AC) Mortality in Hemodialysis (HD) Patients? **Beddhu S,** Cheung AK, Yan G, Greene T, Kaysen G, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G. American Society of Nephrology 2005 Meeting, Philadelphia, PA.
- 2006 Insulin Sensitivity Predicts Better Survival in Non-Diabetic Moderate Chronic Kidney Disease (CKD) Population. Kwan BCH, **Beddhu S.** American Society of Nephrology November 14 - 19, 2006; San Diego, CA.
- 2006 Associations of Body Size with Metabolic Syndrome (MS) and Mortality in Moderate Chronic Kidney Disease (CKD). Kwan BCH, Ramkumar N, Murtaugh M, **Beddhu S.** American Society of Nephrology 2006 Meeting, San Diego, CA
- 2006 Malnutrition Is Not a Misnomer: Diet Influences Survival in hemodialysis (HD) Patients. Ramkumar N, Murtaugh M, Kwan BCH, Kaluvapalle JR, **Beddhu S.** American Society of Nephrology 2006 Meeting, San Diego, CA
- 2008 Is Alkaline Phosphatase (AP) a Therapeutic Target in Hemodialysis (HD) Patients? **Beddhu S,** Ma X, Cheung AK. American Society of Nephrology Meeting, Philadelphia, PA.
- 2011 High Dietary Fiber (DF) Intake Is Associated with ↓Inflammation and Mortality in CKD: National Health and Nutrition Examination Survey (NHANES) III Krishnamurthy VR, Wei G, Chonchol MB, Raphael KL, Greene TH, **Beddhu S.** American Society of Nephrology Meeting, Philadelphia, PA.
- 2011 Estimated Net Endogenous Acid Production and Chronic Kidney Disease Progression in African Americans: The African American Study of Kidney Disease and Hypertension (AASK) Scialla J, Appel L, Astor B, Miller E, **Beddhu S,** Woodward M, Parekh R, Anderson C. American Society of Nephrology Meeting, Philadelphia, PA.
- 2012 Body Composition Affects Serum Creatinine but Not Serum Cystatin C Levels. Almeida NE, Ikizler TA, Zhang Y, Filipowicz R, Morrell G, Wei G, Abraham J, Habib AN, Bjordahl TS, Greene T, Cheung AK, **Beddhu S.** American Society of

- Nephrology Meeting, San Diego, CA.
- 2013 Low Serum Bicarbonate Is Associated with Lower Cardiac Mortality (CM) in Hemodialysis (HD) Patients. Roy AC, Wei G, Filipowicz R, Greene T, Raphael KL, Cheung AK, **Beddhu S**. American Society of Nephrology Meeting Atlanta, GA.
- 2014 Early GFR Decline as a Predictor of Cardiovascular Mortality in Non-CKD Diabetics. **Beddhu S**, Wei G, Constantz E, Chen X, Boucher R, Giri A, Simmons DL, Conroy MB, Lee JJ, Greene T. American Society of Nephrology Meeting Philadelphia, PA.
- 2014 Prevalence, Body Composition and Mortality Associations of Protein Energy Wasting in Non-CKD and CKD in the U.S. **Beddhu S**, Wei G, Boucher R, Constantz E, Chen X, Greene T. American Society of Nephrology Meeting Philadelphia, PA.
- 2015 Sedentary Behavior as a Risk Factor for CKD. Ferranti D, Lyden K, Chen X, Boucher R, Wei G, **Beddhu S**. American Society of Nephrology Meeting San Diego, CA.
- 2016 Effects of Intensive SBP Lowering on Incident Chronic Kidney Disease (CKD) and Cardiovascular (CV) Outcomes in Non-CKD Subgroup in Systolic Blood Pressure Intervention Trial (SPRINT). **Beddhu S**, Rocco MV, Toto RD, Craven T, Greene T, Cheung AK, Kimmel PL, Whelton PK. American Society of Nephrology Chicago, IL.
- 2016 Changing Phenotype of CKD in Diabetes Mellitus (DM) and Its Implications. **Beddhu S**, Cheung AK, Fired LF, Wei G, Boucher RE, Kiani RN, Lewis J, Greene T. American Society of Nephrology Meeting Chicago, IL.
- 2016 Intensive Blood Pressure Lowering Will Prevent over 100,000 Deaths Annually. Joerla T, Tan M, Bress A, Cooper R, Muntner P, **Beddhu S**, Kramer H. American Society of Nephrology Meeting Chicago, IL.
- 2017 Intensive Systolic Blood Pressure (SBP) Control and Incident CKD in Persons with and without Diabetes Mellitus (DM). **Beddhu S**, Cheung AK, Chertow GM, Whelton PK, Boucher RE, Wei G, Kimmel PL, Cushman WC, Greene T. American Society of Nephrology Meeting New Orleans, LA.
- 2017 Influence of Baseline Diastolic Blood Pressure (DBP) Level on the Effects of Intensive Blood Pressure Lowering on Incident CKD in SPRINT. **Beddhu S**, Chertow GM, Cheung AK, Rahman M, Greene T, Wei G, Haley WE, Cushman WC, Whelton PK. American Society of Nephrology Meeting New Orleans, LA.
- 2018 Long-Term Kidney Effects of Intensive (INT) SBP Lowering in Persons with Type 2 Diabetes Mellitus (T2DM): ACCORD BP and ACCORDION. **Beddhu S**, Boucher RE, Wei G, Cheung AK et al. *American Society of Nephrology, Oct 23- 28, San Diego, CA*
- 2018 Influence of Intensive Glycemia Intervention on the Effects of Intensive Systolic Blood Pressure (SBP) Lowering in Type 2 Diabetes Mellitus: Reconciling Results from ACCORD BP and SPRINT. **Beddhu S**, Greene T, Cheung AE, Chertow GM, Kramer, HJ, Kimmel, PL, Boucher RE, Fine, LJ, Wei G, Zhang C, Rahman, M, Oparil S, Ambrosius WT, Bress A, Cutler, JA, Whelton PK, Cushman WC. *American Society of Nephrology. Oct 23 – Oct 28, 2018 San Diego, CA.*
- 2018 Long-Term Kidney Effects of Intensive (INT) SBP Lowering in Persons with Type 2 Diabetes Mellitus (T2DM): ACCORD BP and ACCORDION. **Beddhu S**, Boucher RE, Wei G, Cheung AE, Chertow GM, Ambrosius WT, Cushman WC, Whelton PK, Greene T. *American Society of Nephrology. Oct 23 – Oct 28, 2018 San Diego, CA.*
- 2021 Role of Hypertension in the Risk of Heart Failure in CKD. Hartsell SE, Guo W,

- Boucher RE, Agarwal A, Fang JC, Bress A, Cheung AK, **Beddhu S.** *American Society of Nephrology. Nov 4. Online.*
- 2021 Influence of Baseline Diastolic Blood Pressure on the Effect of Lowering Systolic Blood Pressure on Mild Cognitive Impairment and Probable Dementia. Gupta A, Boucher RE, Wei G, Supiano MA, Burns JM, Navaneethan SD, Gregg LP, Williamson JD, Pajewski NM, **Beddhu S.** *American Society of Nephrology. Nov 4. Online.*
- 2022 Influence of Baseline Diastolic BP (DBP) on the Effects of BP Lowering on Cardiovascular (CV) Outcomes: A Meta-Analysis of NIH BP Trials. Sarwal A, Boucher RE, Hartsell SE, Wei G, Ye, Xiangyang, Shen, J, Chertow GM, Whleton PK, Cheung AK, Greene T, **Beddhu S.** *American Society of Nephrology. Nov 3, Orlando, FL.*
- 2022 Nutritional Status and Cardiorenal Syndrome: Associations of Protein-Energy Wasting and Abdominal Obesity With the Risk of Heart Failure in CKD. Agarwal T, Hartsell SE, Boucher RE, Sammons SR, Sarwal A, Wei G, Beddhu S. *American Society of Nephrology. Nov 3, Orlando, FL.*

Invited/Visiting Professor Presentations

National

- 2005 Heart in Dialysis, 11th International Symposium on Hemodialysis at Tampa, FL
- 2006 Is obesity a risk factor for development and progression of CKD? Obesity in Kidney Disease Session, American Society of Nephrology 2006 Meeting, San Diego, CA
- 2007 Body size and survival in CKD. 2007 NKF Spring Clinical Meeting, Orlando, FL
- 2008 Obesity and Inflammation in CKD, NKF Spring Meeting, Dallas, TX
- 2008 Is Malnutrition a Misnomer? NKF Spring Meeting, Dallas, TX
- 2008 Literature Review: Metabolic Syndrome, ASN Meeting, Philadelphia, PA
- 2009 Is Malnutrition a Misnomer? NKF Spring Meeting, Nashville, TN
- 2010 Reverse epidemiology of Obesity and ESRD Mortality. 2010 Nephrology Update, Cleveland, OH
- 2010 Obesity and CKD – An internist’s perspective. 2010 Nephrology Update, Cleveland, OH
- 2011 The BMI Paradox in ESRD: A Story Half Untold, University of Pittsburg, Pittsburg, PA
- 2011 The Impact of Weight Loss on Progression of CKD and Transplant. 2011 NKF Spring Meeting, Las Vegas NV
- 2011 The BMI Paradox in ESRD: Is It Fat, Muscle or Both? 2011 NKF Spring Meeting, Las Vegas NV
- 2016 Role of Obesity in Diabetic Kidney Disease, American Society of Nephrology Meeting Chicago, IL.
- 2018 The "Obesity Paradox" in Heart and Kidney Disease, 3rd Annual Cardio Renal Connections conference, San Antonio, TX
- 2018 Dyslipidemia – Why Statins Don’t Work in CKD, 3rd Annual Cardio Renal Connections conference, San Antonio, TX
- 2018 Newer High Blood Pressure Guidelines, 3rd Annual Cardio Renal Connections conference, San Antonio, TX
- 2018 Systolic Blood Pressure Goals in Hypertensive Persons without and with Diabetes: Reconciling SPRINT and ACCORD-BP findings, Kansas City NKF Round Table
- 2018 J-Curve: Fact or Fiction? Kansas University, Kansas City, KS
- 2018 The Influence of Low Diastolic BP on Intensive BP Treatment Outcomes. American Society of Nephrology, Oct 23- 28, San Diego, CA

- 2019 Carotid Atherosclerotic Plaque Morphology, Chronic Kidney Disease and CV Outcomes: A SPRINT Ancillary Study. North American Arterial Society Meeting, May, 2019 Iowa City, IA.
- 2019 Can Lifestyle and Diet Make a Difference for Patients with Diabetes and Kidney Diseases? Beddhu S. *American Society of Nephrology*. Nov 9, 2019 Washington, DC.
- 2020 Intensive Management of BP: What More Have We Learned From SPRINT? Beddhu S. *American Society of Nephrology*. Oct 25, 2020 Live-Streamed.
- 2022 Sit Less, Move More! Targeting Sedentary Behavior in Patients with CKD. *American Society of Nephrology meeting scheduled for November 3–6 in Orlando, FL*